IQVIA Receives WCG Pinnacle Award for Excellence in Site Relationships
IQV(NYSE:IQV) RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, has been honored with the WCG Pinnacle Award for Site Relationships in Professionalism and Communication. The award recognizes IQVIA’s commitment to building strong, collaborative partnerships with clinical trial sites worldwide. The award is based on feedback from over 12,000 par
IQVIA Announces Launch of Clinical Trial Financial Suite, a Next-Generation Platform for Integrated Financial Management
IQV(NYSE:IQV) RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today announced the launch of its Clinical Trial Financial Suite (CTFS), an AI-enabled platform orchestrating all financial aspects of clinical trials. CTFS is designed to eliminate inefficiencies created by siloed systems and fragmented processes. In contrast to other industry of
IQVIA Announces CFO Transition in Early 2026
IQV(NYSE:IQV) RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences and healthcare industries, today announced a planned leadership transition in its finance organization. Michael Fedock, currently Senior Vice President of Financial Planning & Analysis, has been appointed Executive Vice President and Chief Financial Officer, effective February 28, 2
IQVIA and Flagship Pioneering Announce Strategic Collaboration to Accelerate the Development of Breakthrough Life Sciences Companies
IQVRESEARCH TRIANGLE PARK, N.C. and CAMBRIDGE, Mass., Aug. 28, 2025 /PRNewswire/ -- IQVIA (NYSE: IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, and Flagship Pioneering, the bioplatform innovation company, today announced a...
IQVIA and Veeva Announce Long-term Clinical and Commercial Partnerships and Resolution of All Disputes
IQVGlobal partnerships to help customers improve clinical and commercial efficiency and effectiveness RESEARCH TRIANGLE PARK, N.C. and PLEASANTON, Calif., Aug. 18, 2025 /PRNewswire/ -- IQVIA (NYSE: IQV) and Veeva Systems (NYSE: VEEV) today announced global clinical and commercial...
IQVIA and Veeva Announce Long-term Clinical and Commercial Partnerships and Resolution of All Disputes
IQVRESEARCH TRIANGLE PARK, N.C. & PLEASANTON, Calif.--(BUSINESS WIRE)--IQVIA (NYSE: IQV) and Veeva Systems (NYSE: VEEV) today announced global clinical and commercial partnerships and the complete resolution of all pending legal disputes. Under the terms of the long-term agreement, customers can use software, data, technology, and service offerings from Veeva and IQVIA together in a simple and efficient way. The global partnerships make it easy for customers to work with IQVIA and Veeva in key are
Kexing Biopharm Enters Strategic Partnership with IQVIA to Accelerate Global Expansion
IQVSHENZHEN, China, Aug. 11, 2025 /PRNewswire/ -- Kexing Biopharm (688136.SH) has officially entered into a comprehensive strategic partnership with IQVIA(NYSE:IQV), a global leader in clinical research services, commercial insights and healthcare intelligence to the life sciences and...
IQVIA Health Research Space Wins 2025 MedTech Breakthrough Award for ‘Best Mobile App for Patient Engagement’
IQVRESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, has been selected as the winner of the “Best Mobile App for Patient Engagement” in the ninth-annual MedTech Breakthrough Awards program. IQVIA’s breakthrough Health Research Space platform allows direct-to-patient data collection and engagement with patient-facing mobile apps that
Nvidia Just Partnered With A Weight-Loss Giant, But It's Not About Pills
IQVNvidia teams up with Novo Nordisk and IQVIA to boost AI-powered drug development and streamline complex pharmaceutical workflows.
IQVIA Unveils New AI Agents Built With NVIDIA To Speed Up Drug Discovery And Streamline Clinical Trials
IQVIQVIA Launches New AI Agents for Life Sciences and Healthcare
IQVRESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, unveils AI agents at GTC Paris. IQVIA’s new custom-built AI agents using NVIDIA technology are designed to enhance workflows and accelerate insights for life sciences. These live applications of agentic architectures illustrate how IQVIA AI and deep domain expertise are transformi
IQVIA Stock: Stuck In A Time Spiral - Value Play Or Bull Trap?
IQVIQVIA stock may look ready for a breakout, but Adhishthana analysis reveals a complex time spiral that could last until 2030.
Rein Therapeutics Doses First Patient in Phase 2 Trial for IPF Drug LTI-03
IQVP/E Ratio Insights for IQVIA Hldgs
IQVJP Morgan Maintains Overweight on IQVIA Hldgs, Lowers Price Target to $177
IQVIQVIA Collaborates With Contract Research Organization Arm Of Sarah Cannon Research Institute, SCRI Development Innovations, To Transform Oncology Trials For Biopharma Partners Worldwide
IQVDeep Dive Into IQVIA Hldgs Stock: Analyst Perspectives (10 Ratings)
IQVMizuho Maintains Outperform on IQVIA Hldgs, Lowers Price Target to $190
IQVBaird Maintains Neutral on IQVIA Hldgs, Lowers Price Target to $161
IQVUBS Maintains Buy on IQVIA Hldgs, Lowers Price Target to $185
IQVBarclays Maintains Equal-Weight on IQVIA Hldgs, Lowers Price Target to $165
IQVIQVIA Beats Q1 Earnings Expectations Despite Sector Uncertainty, Company Navigating Market Conditions 'Effectively' Says CEO
IQVIQVIA reports Q1 EPS of $2.70 and revenue of $3.83 billion, raises 2025 sales outlook and highlights strong growth in analytics and R&D pipeline metrics.
IQVIA Hldgs Affirms FY2025 Adj EPS Guidance of $11.70-$12.10 vs $11.83 Est; Raises FY2025 Sales Guidance from $15.72B-$16.13B to $16.00B-$16.40B vs $15.87B Est
IQVIQVIA Hldgs Q1 Adj. EPS $2.70 Beats $2.63 Estimate, Sales $3.83B Beat $3.77B Estimate
IQVBeyond The Numbers: 12 Analysts Discuss IQVIA Hldgs Stock
IQVHSBC Downgrades IQVIA Hldgs to Hold, Lowers Price Target to $160
IQVTruist Securities Maintains Buy on IQVIA Hldgs, Lowers Price Target to $216
IQVBarclays Downgrades IQVIA Hldgs to Equal-Weight, Lowers Price Target to $170
IQVCitigroup Maintains Neutral on IQVIA Hldgs, Lowers Price Target to $210
IQVJP Morgan Maintains Overweight on IQVIA Hldgs, Lowers Price Target to $232
IQVIQVIA Collaborates With NVIDIA To Combine IQVIA Connected Intelligence With NVIDIA AI Foundry To Help Transform Life Science Processes From R&D Through Commercialization
IQVStephens & Co. Initiates Coverage On IQVIA Hldgs with Overweight Rating, Announces Price Target of $250
IQV(IQV) - Analyzing IQVIA Hldgs's Short Interest
IQVLeerink Partners Reiterates Outperform on IQVIA Hldgs, Lowers Price Target to $248
IQVPeering Into IQVIA Hldgs's Recent Short Interest
IQVRBC Capital Reiterates Outperform on IQVIA Hldgs, Maintains $270 Price Target
IQVJP Morgan Maintains Overweight on IQVIA Hldgs, Lowers Price Target to $240
IQVTruist Securities Maintains Buy on IQVIA Hldgs, Lowers Price Target to $265
IQVMorgan Stanley Maintains Overweight on IQVIA Hldgs, Lowers Price Target to $265
IQVBTIG Maintains Buy on IQVIA Hldgs, Lowers Price Target to $260
IQVTD Cowen Maintains Buy on IQVIA Hldgs, Lowers Price Target to $255
IQVDeutsche Bank Maintains Buy on IQVIA Hldgs, Lowers Price Target to $265
IQVBarclays Maintains Overweight on IQVIA Hldgs, Lowers Price Target to $255
IQVGoldman Sachs Maintains Buy on IQVIA Hldgs, Lowers Price Target to $250
IQVRBC Capital Reiterates Outperform on IQVIA Hldgs, Maintains $270 Price Target
IQVBaird Maintains Neutral on IQVIA Hldgs, Lowers Price Target to $223
IQVIqvia Holdings Exec Says Q4 Adj EPS Is Expected To Be Between $3.08-$3.18
IQVIqvia Holdings Exec Says Expect Q4 Revenue To Be Between $3.9B-$3.95B
IQVIQVIA Forecasts 2024 Adjusted EPS Of $11.10-11.20 Compared To Prior Guidance Of $11.10-$11.30 And Consensus Of $11.21
IQVIQVIA Forecasts 2024 Revenues Of $15.35B-$15.4B Compared To Prior Guidance Of $15.425B-$15.525B And Consensus Of $15.471B
IQV